Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$8.0M of $10.0M
Filed2026-08-20
Days since filing44
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-05
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Sara RatnerExecutive Officer · Director
- Anna FaginDirector
- Shane SpottsExecutive Officer · Director
- Miguel TrianaDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged79.5% sold1.9 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-240
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.